Stereologic Estimation of Volume-Weighted Mean Nuclear Volume as a Predictor of Prognosis in “Thin” Malignant Melanoma  by Binder, Michael et al.
Stereologic Estimation of Volume-Weighted Mean 
Nuclear Volume as a Predictor of Prognosis in "Thin" 
Malignant Melanoma 
Michael Binder, Irene Dolezal, Klaus Wolff, and Hubert Pehamberger 
Department of Dermatology I, University of Vienna, Vienna, Austria 
At present, tumor invasion represents the most reliable prog-
nostic factor for primary malignant melanoma. The 10-year 
survival rate of "thin" melanomas (Breslow < 0.76 mm) is 
more than 95%, but approximately 5% of these low-risk 
tumors do metastasize. 
In an attempt to determine prognostic markers for "thin" 
melanomas we investigated the volume-weighted mean nu-
clear volume (Vv ) of primary melanomas with tumor inva-
sions below 0.76 mm in 32 patients. Ten of these patients had 
developed melanoma metastases within a mean follow-up 
period of 49 months; 22 patients who had not developed 
metastases and who were comparable with regard to clinical 
and histologic criteria as well as to follow-up period were 
selected as a comparison group. Vv was determined by com-
puter-assisted image analysis (IBAS 20, Kontron, Germany) 
on hematoxylin-eosin - stained sections employing stereolo-
gic estimation of the volume-weighted mean nuclear vol-
T he increasing incidence and mortality rate of malig-nant melanoma is well documented [1- 4) and so is the seemingly paradoxical improvement of prognosis, which, however, is due to earlier recognition of this tumor [5,6). In general, the prognosis of "thin" malig-
nant melanoma, i.e., tumors with a Breslow thickness of less than 
0.76 mm, is excellent [7,8) with a 5-year survival rate of approxi-
mately 95% [7 - 12). 
The actual rate of metastases occurring in these patients is still a 
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Abbreviations: 
CCD: charge coupled device 
Fcnlc: circularity shape fact"or 
FSHAPE: aspect ratio 
LMM: lentiginous malignant melanoma 
NS: statistically not significant 
SO: standard deviation 
SO Feme' standard deviation of circularity shape factor 
SO F SHAPE: standard deviation of aspect ratio 
SSM: superficial spreading melanoma 
Vv : volume weighted mean nuclear volume 
ume. In addition, two-dimensional morphometric parame-
ters (nuclear area and shape factors) as well as clinical (sex, 
age, location) and histologic characteristics (Breslow's thick-
ness, Clark's level, and growth patterns) were recorded. 
The mean Vv (± SO) of primary melanomas with subse-
quent metastatic course was 273 flm3 (± 81.3), whereas pri-
mary melanoma lesions without subsequent metastases ex-
hibited a significantly lower Vv of .154 I!-m3 (± 25.3) 
(p = 0.0008). On the other hand, two-dimenSiOnal morpho-
metric and clinical and histologic parameters did not corre-
late with prognosis. 
Vv thus seems to represent a powerful and independent 
prognostic marker for "thin" primary melanomas. Assess-
ment of Vv may provide a valuable tool in selecting patients 
with high-risk stage I, Breslow < 0.76 mm, melanoma for 
adjuvant therapy.] Invest DermatoI99:180-183, 1992 
matter of debate. The incidence of metastases in patients with 
"thin" malignant melanoma has been reported in different studies 
to range from 0 to 22% with an estimated mean of5% [7 ,8,11-14). 
Thus, there must exist a subset of "thin" malignant melanoma that 
is lethal and the recognition of patients with such high-risk "thin" 
malignant melanomas appears to be of paramount importance. 
In the present study, 32 patients with "thin" malignant melano-
mas, ten of whom had developed subsequent metastases, were in-
vestigated for morphometric and stereologic criteria that might 
predict the outcome of metastatic disease. We found the stereologic 
estimation of volume-weighted mean nuclear volume (V
v
) a reli-
able predictive criterion. Here we report that the Vv of patients with 
"thin" melanomas developing metastatic disease is significantly · 
higher than in comparable, non-metastatic tumors and thus permits 
discrimination of high-risk from low-risk "thin" melanomas. 
PATIENTS AND METHODS 
Patients Since 1970 more than 1800 melanoma patients have 
been registered in our computerized pigmented-lesion database. In 
the last 10 years, 255 patients with I?rimary melanoma lesions less 
than 0.76 mm according to Breslow [13] were identified [4]. Ten of 
these patients had been selected because they had developed metas-
tases within an observation period of 6 years. Twenty-two patients 
who had not developed metastatic disease and who were compara-
ble with regard to sex, age, site, type of melanoma, invasion level , 
and duration of follow-up served as a comparison group. All study 
patients had received surgical treatment only, consisting of wide 
local excision without elective regional lymph-node dissection. Ad-
juvant immunotherapy and/or chemotherapy had not been given 
prior to the development of metastases. 
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Table I. Patient Characteristics· 
Patients with Patients without 
Characteristic Metastases Metastases Statistics 
Number of patients 10 22 
Sex 
Male (percent) 5 (50) 7 (32) 
Female (percent) 5 (50) 15 (68) NS 
Mean age (years) 55 46 
Minimum/maximum 33/68 26/74 NS 
Site 
Trunk 7 (70%) 10 (45%) 
Limbs 3 (30%) 12 (55%) NS 
Growth pattern 
9 (90%) 21 (95%) SSM 
LMM t (10%) 1 (5%) NS 
Clark's level 
II 5 (50%) 10 (45%) 
III 4 (40%) 1 t (50%) 
IV 1 (10%) t (5%) NS 
Mean Thickness (mm) 0.57 0.64 
SD 0.16 0.09 NS 
Minimum/maximum 0.30/0.75 0.50/0.75 
Mean duration of fol-
low-up (month) 49.1 65.5 NS 
II Percent values arc rounded to the nearest integer. 
In all patients the diagnosis of primary malignant melanoma had 
been confirmed by histopathology. Date recorded and available for 
evaluation included age, sex, localization of primary tumor, histo-
pathologic type of melanoma, level of invasion according to Clark 
et al [15], and tumor thickness according to Breslow [13] . 
Metastases diagnosed at fo llow-up were recorded as regional 
lymph-node metastases, cutaneous/subcutaneous metastases, and/ 
or visceral disease. Patients had been examined for evidence of meta-
static disease every 3 months for 5 years and subsequently every 6 
months . In addition, chest X-ray, abdominal ultrasound, and bone 
scan were done every 6 or 12 months, respectively. Clinical and 
pathologic parameters evaluated are listed in Table I. 
Histopathologic Specimens Histologic sections (4 - 5 J1.m) 
were cut from routinely processed, paraffin-embedded tissue blocks, 
and stained with hematoxylin and eosin and processed for stereolo-
gic and morphometric evaluation. 
Stereologic Methods An !BAS 20 automatic image analyzer 
(Zeiss, Kontron, Germany) was equipped with a Zeiss Axiomat 
microscope. Using this system with a 40 X lens the fields of vision 
were grabbed into the computer by a Sony DXC 325-P three CCD 
chip color camera at a final resolution of 768 X 512 pixels. The 
absolute magnification on the high-resolution screen was about 
1300 X. The system was calibrated to measure microns of lengths 
and was corrected for distortion between the x- and y-axes. 
After appropriate noise reduction and contrast enhancement, ten 
microscopic fields in each tumor were studied in two to four sec-
tions, excluding tumor areas with necrosis, heavy pigmentation, or 
massive inflammation. Selection of measured fields was done by 
random assignment over the whole tumor area. Both superficial and 
deeper portions of the melanomas were included in the sampling 
procedure by the computer. Measurements were performed with-
out knowledge of data and the outcome of patients . 
The methodologic and mathematical basis of estimation of the 
three-dimensional volume-weighted mean Vv has been described 
previously by Gundersen and Jensen [16,17] . 
An orientation frame was superimposed on the TV screen with its 
left-hand edge perpendicular to the cutaneous surface of the tumor, 
ensuring that the measurements were carried out on so-called verti-
cal sections [18]. 
A random number between 0 and 97 was generated by the com-
puter, and this number determined the starting orientation number 
of the linear elements on a superimposed test probe. For each fie ld of 
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vision the number 10 was added to the initial number so that the 
direction of the test system was weighted by the sine of its angle 
from the vertical axis . If a point of the test probe hits a nuclear 
profile the orientated test line was measured using the digitizer 
tablet interactively. By multiplying the mean of individually cubed 
intercept lengths by n/3 an unbiased estimate of the volume-
weighted mean Vv was obtained. The mean number of point sam-
pled nuclear intercepts was 132 per melanoma (range, 68-153) 
from ten fields of vision. 
Almost every step of the procedure, including data sampling and 
computation of data described above, was automatically executed by 
the computer, but the measurement of point-sampled intercept 
lengths was done in an interactive way using the digitizer tablet (see 
Fig 1). 
Morphometric Methods The two-dimensional parameters 
were determined in a combined approach (automatically and inter-
actively). Briefly, image processing was performed as follows . For 
acquisition of images the red channel of the color camera was used; 
the signal of this channel obtains the highest contrast between ob-
jects of interest (blue stained) and background. Image enhancement 
was performed by normalization of the image and application of a 
contour-enhancement algorithm. Image segmentation itself was 
done using threshold segmentation. Contours extracted from the 
binary image were displayed in an overlay superimposed over the 
original image. In most cases more than 60% of nuclei were 
correctly identified. Using the original image the final segmenta-
tion was done interactively (i.e., completion of incorrectly seg-
mented nuclei). At this step rejection of artifacts was possible using 
the digitizer board mouse. Derived from previous experiments we 
found that the combined approach of segmentation on routine slides 
is less time consuming and shows a very good correlation with 
strictly manually segmented nuclei. 
The same orientation frame as applied for stereologic measure-
ments was used for measuring the fol lowing two-dimensionalmor-
phometric parameters: nuclear area, circularity shape factor (Fcmc 
defined as (4' n' area)/perimeter2) and aspect ratio of the nucleus 
(FsHAPE defined as DM1N/DMAX) [19 - 21] . 
Statistics Comparisons of grSlUped data in Table I were analyzed 
by chi-square test and U test. Statistical significance of differences of 
data in Table II was tested with the pooled data of the two groups 
using the nonparametric Wilcoxon rank-sum test [22- 24]. P values 
ofless than 0.05 were considered to indicate statistical significance. 
Figure 1. Screen copy of a vertical section of a "thin" malignant melanoma 
at high-power field (magnification Xl113). The vertical axis has been 
aligned with the left-hand edge perpendicular to the cutaneous surface at 
low-power magnification. The starting angle of the test probe is generated 
randomly by the computer. If a test point hits a nuclear profile the nuclear 
intercept is measured using a digitizer board. 
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Table II. Morphometric (Two-Dimensional) and Stereologic (Three-Dimensional) Parameters 
Parameter (±SO) 
Number of patients 
Nuclear area (tim2) 
SO nuclear area 
F,h,pc 
SO F,h,pc 
Fcirc 
SO Fe;" 
Vv (tim' ) 
RESULTS 
Patients with Metastases 
10 
25.48 (±6.08) 
10.46 (±2.60) 
0.62 (±0.04) 
0.14 (±0.02) 
0.81 (±0.03) 
0.10 (±0.02) 
272.63 (±81.36) 
Clinical Parameters The clinical parameters of the two groups 
of patients studied are listed in Table 1. As is shown, no significant 
difference was present between both groups with regard to clinical 
and pathologic features . Thus from a statistical point of view the 
groups were comparable. 
Two-Dimensional Morphometric Estimations The mean 
nuclear area ranged from 18 to 36 11m2 with a mean of 25.5 11m2 
(SD ± 6.08) in the group of patients with metastatic disease and was 
14 to 32 11m2, with a mean of 22.5 11m2 (SD ± 4.18), in the group 
without metastases. The mean nuclear area thus was larger in pa-
tients with subsequent metastatic disease than in patients without 
metastases, but there was no statistically significant difference (see 
T able II). In addition, aspect ratio of the nucleus (FsHAPE) as well as 
circularity shape factor (Feme) did not differ in both groups of 
patients investigated (see Table II). 
Stereologic Estimation of Volume-Weighted Mean Vv The 
V v of "thin" primary melanomas with subsequent metastatic course 
varied from 155 to 457 11m3 with a mean of 272.63 11m3 (SD ± 
81.3). In the group of patients without metastases, Vv varied from 
102 to 199 11m3 with a mean of 153.73 11m3 (SD ± 25.3). This 
difference was found to be highly significant (p = 0.0008). "Thin" 
melanomas with subsequent metastases thus exhibit a significantly 
higher Vv than melanomas that do not metastasize (see Table II, 
Fig 2). 
DISCUSSION 
At present the prognosis of malignant melanoma is evaluated on the 
bas is of cli nical and histopathologic criteria. Sex [25,26], age [27]. 
anatomic site [28] of the tumor, and clinical evidence of ulceration 
[29] have been shown to influence prognosis. Histopathologically, 
the growth pattern [30], cell rype of melanoma [31], evidence of 
regression or ulceration [27,31,32], mitotic rate [33], and lympho-
cytic infiltration [34] are considered to be of prognostic importance. 
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Figure 2. Volume-weighted mean Vv is significantly higher in patients 
with "thin" malignant melanoma who developed metastases than in their 
non-metastatic counterparts. Values are depicted in means ±SO. 
Patients without Metastases 
22 
22.45 (±4.18) 
9.64 (±2.05) 
0.62 (±0.06) 
0.15 (±0.03) 
0.82 (±0.05) 
0.12 (±0.03) 
153.73 (±25.30) 
Statistics (p values) 
NS 
NS 
NS 
NS 
NS 
NS 
0.0008 
However, so far the most important predictive value is assigned to 
the evaluation of the micro-invasion level of the tumor as assessed 
by the invasion levels described by Clark et al [15] and measurement 
of tumor thickness according to Breslow [13] . Multivariable analy-
ses of single prognostic values enable the identification of indepen-
dent predictors of survival [27,35] . Based on a model of tumor 
progression in stage I melanoma, Clark et al [36] have shown that 
patients with radial growth-phase tumors have survived for a mini-
mum of 8 years and the identification of independent prognostic 
predictors such as mitotic rate, tumor-infiltrating lymphocytes, 
tumor thickness, anatomic site, gender, and regression allows an 
84.1 % accuracy in the prediction of survival in vertical growth-
phase tumors. However, there is consensus that tumor thickness 
according to Breslow is the single most powerful prognostic vari-
able [37] . 
On the other hand, there is sufficient evidence that in stage I 
melanoma with tumor invasion of less than 0.76 mm, the tumor 
thickness of Breslow does not seem to provide infallible prognostic 
information [7,36]. There is no question that metastasis and death 
from "thin" melanomas is rare, but several reports exist document-
ing that an estimated mean of 5% [7,8,11-14] of patients with 
"thin" melanoma develop metastases. So far, studies have failed to 
define significant clinical, histologic, and/or immunologic markers 
for this subgroup. 
Sorensen [38] has already shown the predictive value ofVv deter-
mination in the assessment of prognosis in clinical stage I and II 
melanomas. In the present study we now show that the stereologic 
estimates of mean Vv of patients with "thin" melanomas 
« 0.76 mm) and subsequent metastases is significantly larger 
(Vv = 273 11m3) than the Vv of melanoma patients (Vv = 154 11m3) 
who do not develop metastases. In contrast, two-dimensional mor-
phometric parameters such as nuclear area, aspect ratio, or circular-
ity shape factor did not prove to be statistically different between the 
two groups of patients. The two-dimensional morphometric param-
eters have already been shown to be of greater value in classification 
than in prognostication [39 - 41]. 
In malignant melanoma vertical and horizontal growth patterns 
cause directional orientation of tumor cells. In our study, anisotropy 
was eliminated by individually weighting the lines of the test probe 
as a function of their angle from the vertical axis. Shape and orienta-
tion-independent estimates of nuclear V v are therefore more accu-
rate than two-dimensional parameters. Estimates of Vv are shape-
and orientation-independent three-dimensional estimates and thus 
combine information about both volume and variation of volume. 
Thus, Vv increases not only when the ordinary number-weighted 
mean V v increases; a rise in V v is also observed with an increasing 
variability or heterogeneity of nuclear volume itself. 
W e do not know the mechanisms that lead to a large nuclear Vv in 
certain melanomas with a subsequent detrimental course and not in 
others that biologically appear more "benign" and do not metasta-
size so rapidly. A recent study shows that there is a correlation of 
karyometric parameters and proliferative activity in cutaneous me-
lanocytic tumors, as defined by the immunohistochemical activity 
of Ki-67 antibody [42]. 
In conclusion, our data show that 1) patients with "thin" malig-
nant melanomas do carry a risk of developing metastatic disease, and 
that 2) estimation of volume-weighted mean V v is a sensitive param-
eter for identification of high-risk "thin" melanomas. Thus, vol-
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ume-weighted mean V v seems to represent a powerful and indepen-
dent prognostic marker for "thin" primary melanomas. Assessment 
ofV
v 
may therefore prove ~ valuable tool in selecting patients with 
high-risk melanoma for adjuvant therapy. 
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